title: Pityriasis rosea in a patient with Behçet's disease treated with interferon alpha 2A.
abstract: Interferons have been used for the treatment of many diseases because of their immunomodulatory, antiviral, antitumoral, and antiproliferative effects. Systemic interferon alpha 2a (IFN-alpha 2a) is also efficacious in the management of Behçet's disease (BD). Many adverse cutaneous reactions related to IFN-alpha have been reported. In the light of the current literature, we report here the first case of Pityriasis rosea (PR) that developed while receiving IFN-alpha 2a for BD. However, since this is the first report on this association, further observations are needed to determine their clinical relevance.
authors.affiliation: Department of Dermatology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: C
authors.initials: C
authors.lastname: Durusoy
authors.forename: E
authors.initials: E
authors.lastname: Alpsoy
authors.forename: E
authors.initials: E
authors.lastname: Yilmaz
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy*; D001707:Biopsy, Needle; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D017515:Pityriasis Rosea / Q000139:chemically induced* / Q000473:pathology; D011379:Prognosis; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins